Press releaseGlobe Newswire
PDS Biotechnology
PDSB · NASDAQ
$0.9605+$0.044 (+4.80%)TodayMarket closed ·
Prev close $0.9165
Latest news
- Press releaseGlobe Newswire
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
- Press releaseGlobe Newswire
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsHenry Khederian
PDS Biotech Stock Surges Tuesday: What's Driving the Action?
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
- NewsAvi Kapoor
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
- NewsAvi Kapoor
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August
- Press releaseGlobe Newswire
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
- Press releaseGlobe Newswire
PDS Biotech Reports Second Quarter 2026 Financial Results
- NewsVandana Singh
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releaseGlobe Newswire
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
- News
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
- News
Earnings Scheduled For May 13, 2026
- Press releaseGlobe Newswire
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
- Press releaseGlobe Newswire
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
- News
Earnings Scheduled For March 30, 2026
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
- News
Earnings Scheduled For November 13, 2025
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
- Press releasePRNewswire
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
- Press releaseGlobe Newswire
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- News
Insights Ahead: PDS Biotechnology's Quarterly Earnings
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
- News
Uncovering Potential: PDS Biotechnology's Earnings Preview
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.